Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.
A scathing article in the New York Times on June 21, 2024 did an excellent service to Americans facing the highest price of drugs in the world. While the social media and the stakeholders blame drug companies, insurers, or a dysfunctional federal government, the real culprits are the 3 big pharmacy benefits managers (PBMs; CVS Health, Cigna, and UnitedHealth Group), hired by employers and governments. If they were stand-alone companies, the 3 biggest PBMs would each rank among the top 40 US companies by revenue. The largest, Caremark, generates more revenue than Ford or Home Depot.
PBMs have been around since the late 1950s. They initially handled requests mailed in by pharmacies and patients seeking reimbursement for the costs of prescription drugs. Over the decades, PBMs have had different owners, including drug makers and large chains of pharmacies. They were often credited with saving money for patients and employers, including in the early 2010s when they embraced a new wave of generic drugs. They kept a slice of the savings for themselves. The modern PBM emerged in 2018. The giant health insurers Aetna and Cigna were trying to achieve the growth demanded by Wall Street. They sought to merge with the PBMs, whose profits were soaring. Aetna and CVS combined. Cigna bought Express Scripts (UnitedHealth had built its PBM).
The job of the PBMs is supposedly to reduce drug costs. Instead, they frequently do the opposite. A New York State investigation found that they steer patients toward pricier drugs, charge steep markups on what would otherwise be inexpensive medicines, and extract billions of dollars in hidden fees, a New York State investigation found.
Most Americans get their health insurance through a government program like Medicare or through an employer, which pays for 2 different types of insurance for each person. One type covers visits to doctors and hospitals, handled by an insurance company. The other pays for prescriptions. That is overseen by a PBM who negotiates with drug companies, pays pharmacies, and helps decide which drugs patients can get at what price. In theory, everyone saves money. But the PBMs have excellent public relations campaigns: “We’re good at what we do,” Jon Mahrt, president of UnitedHealth’s PBM, Optum Rx, said in an interview. The leading lobbying group for the PBMs says that in 2022, they saved their clients and patients $286 billion. But those savings appear to be primarily a mirage, a product of a system where prices have been artificially inflated so that major PBMs and drug companies can boost their profits while taking credit for reducing prices. This is how the system works:
Many patients learn about the existence of PBMs only when they have a problem getting medications and spend hours navigating a byzantine system of approvals and restrictions. However, the PBMs’ business practices touch virtually every American family. Even people who don’t take prescription drugs end up paying higher insurance premiums and taxes because of inflated drug costs.
In Washington and state capitals, lawmakers, regulators, and attorneys have suggested that the benefit managers may be inflating drug prices and engaging in anticompetitive behavior.
The Senate bill S127—Pharmacy Benefit Manager Transparency Act of 2023 in 118th Congress (2023-2024—would generally prohibits PBMs from engaging in certain practices when managing prescription drug benefits under a health insurance plan, including charging the plan a different amount than the PBM reimburses the pharmacy. The bill also prohibits PBMs from arbitrarily, unfairly, or deceptively (1) clawing back reimbursement payments or (2) increasing fees or lowering reimbursements to pharmacies to offset changes to federally funded health plans. PBMs are not subject to these prohibitions if they (1) pass along 100% of any price concession or discount to the health plan and (2) disclose specified costs, prices, reimbursements, fees, markups, discounts, and aggregate payments received concerning their PBM services. Further, PBMs must report annually to the Federal Trade Commission (FTC) specific information about payments received from health plans and fees charged to pharmacies. The FTC and state attorneys general are authorized to enforce the bill's provisions.
It would turn out to be a seminal moment, one that would rapidly and radically change the American health care system by further shifting power into the hands of giant conglomerates and away from employers and patients, but dozens of such bills in Congress have come and sat there for years; the lobby of PBMs is indeed influential and why not when they have the resources to lobby. Only the US Congress can do something to alleviate the cost of drugs.
Biosimilars are supposed to reduce the cost to patients substantially, but so far, the prices for biosimilars are typically 15% to 35% lower than their respective brand-name reference biologic. One of the causes of this minor change is the role of PBMs. What good are the biosimilars if the PBM maintains them unaffordable?
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.